SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI (SOAR)
|ClinicalTrials.gov Identifier: NCT01182376|
Recruitment Status : Completed
First Posted : August 16, 2010
Results First Posted : February 19, 2016
Last Update Posted : February 19, 2016
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: dronedarone Drug: Placebo||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Placebo Comparator: Placebo
Half of the patients will be assigned placebo.
Placebo will be administered by the patient's team according to established guidelines.
Experimental: Multaq® (dronedarone)
Half of the patients will be prescribed dronedarone.
Dronedarone will be prescribed by the patient's team according to established guidelines.
Other Name: Multaq®
- LA Fibrosis [ Time Frame: baseline, 1 year ]The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01182376
|Principal Investigator:||Nassir F Marrouche, MD||University of Utah|